Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1500 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
Biotech Daily Editorial: Covid-19 Spruikers, Please Stop ! Dr Boreham's Crucible: Mesoblast Zelira: Marijuana ZLT-101 'Effective For Insomnia' FDA Clears Mesoblast Remestemcel-L For Covid-19 ARDS Biotech Daily Editorial: Covid-19 Coronavirus Claims Dr Boreham's Crucible Special: Covid-19 Biotech Daily Editorial: 2019-nCoV Coronavirus (Covid-19) All The Dope On Medicine, Marijuana, Cannabis & Hemp
14-Year Biotech Data: Big Caps Up 963%, BDI-40 Up 450%, ASX200 Up 16% YTD: Big Caps Up 36%, BDI-40 Up 30%, ASX200 Down 11%
July 1, 2020 For the 14 years since inception, the BDI-40 (which does not include the three Big Caps of Cochlear, CSL and Resmed) was up 333.8 percent, from a collective market capitalization of $3,563 million at June 30, 2006 to $15,455 million, last night.
By comparison, the benchmark ASX200 was up 16.2 percent for the 14-year period.
Adjusting the BDI-40 for company departures, equivalent to the ASX200 methodology, the BDI-40 was up 449.5 percent.
The collective market capitalization of the three Big Caps rose 36.0 percent for the 12 months to June 30 and 2.8 percent for the month of June.
For the 14 years, the collective market capitalization for the three Big Caps climbed 962.7 percent from $17,156 million to $182,316 million.
CSL slipped 0.2 percent in June to $130,312 million, Cochlear shed 2.4 percent to $12,410 million, but Resmed was up $5,492 million or 16.1 percent to $39,594 million.
For the year to June 30, Resmed rose 60.9 percent, CSL climbed 33.6 percent and Cochlear was up 4.2 percent.
In June, 12 BDI-40 companies were up (nine by more than 10 percent), 27 fell (15 by more than 10 percent) and one was unchanged.
For the 12 months to June 30, the best performing biotech company was Opthea up 280.2 percent for the year, despite falling 20.5 percent in June. Mesoblast was up 168.1 percent for the year, followed by Genetic Signatures (119.3%) and Polynovo (64.9%). Pharmaxis was the BDI-20’s worst, down 74.3 percent for the year, with Ellex down 44.1 percent.
From smaller bases in the Second 20, Dimerix improved 430.8 percent to $69 million, followed by Oncosil (190.1%), Imugene (131.0%), Kazia (104.5%) and LBT (100.0%).
Outside the BDI-40, Phylogica climbed 374.6 percent to $337 million for the year to June 30, 2020, followed by Pharmaust up 370.0 percent to $47 million, Imagion (320.0%), Recce (295.7%), Tali (280.0%), Memphasys (214.3%) and Mach7 (197.2%).
The 21 companies in Cannabis Corner fell a further 15.2 percent in June and down 58.9 percent for the year, with most companies falling for both the month and the year to June 30. The exceptions were Bod, Esense, Lifespot, Palla Pharma and Zelira.
On the Nasdaq, Queensland’s Protagonist was up 28.3 percent in June to $912 million and up 125.7 percent for the year, Redhill (with Australian assets) was down 9.2 percent for the month but up 30.0 percent for the year, with Eyepoint (Psivida) down 14.9 percent in June and down 44.8 percent for the year.
BDI-40 v S&P ASX200 Jun 30, 2006 to June 30, 2020
 5-Year Big Caps (Cochlear, CSL, Resmed) to June 30, 2020
 BDI-40 ($m) v S&P ASX200 – Year to June 30, 2020
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At June 30, 2020
* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear
Cynata, Mesoblast, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in.